Response to: 'Tofacitinib for the treatment of polyarteritis nodosa: a literature review'. Correspondence on 'Tofacitinib for polyarteritis nodosa: a tailored therapy' by Rimar
et al
Ann Rheum Dis
.
2022 Oct;81(10):e205.
doi: 10.1136/annrheumdis-2020-218790.
Epub 2020 Sep 9.
Authors
Doron Rimar
1
,
Abid Awisat
2
,
Lisa Kaly
2
,
Gleb Slobodin
2
,
Itzhak Rosner
2
,
Michael Rozenbaum
2
,
Shira Ginsberg
2
,
Elina Starosvetsky
3
,
Ayelet Alpert
4
,
Shai Shen-Orr
4
Affiliations
1
Rheumatology, Bnai-Zion medical center, Haifa, Israel doronrimar@gmail.com.
2
Rheumatology, Bnai-Zion medical center, Haifa, Israel.
3
Department of Immunology, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Haifa, Israel.
4
Department of Immunology, Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
PMID:
32907803
DOI:
10.1136/annrheumdis-2020-218790
No abstract available
Keywords:
biological therapy; cytokines; systemic vasculitis.
Publication types
Review
Letter
Comment
MeSH terms
Humans
Piperidines
Polyarteritis Nodosa* / drug therapy
Pyrimidines / therapeutic use
Substances
Piperidines
Pyrimidines
tofacitinib